Solid Biosciences SLDB 深 滬
等待開盤 09-11 09:30:00 美东时间
5.24
+0.240
+4.80%
華盛通- 最 高5.33
- 今 開5.02
- 成交量 110.54万股
- 最 低 4.98
- 昨 收 5.00
- 總市值 4.08亿
- 52周最高 8.01
- 市盈率 靜 --
- 換手率 1.42%
- 52周最低 2.41
- 委 比 97.91%
- 總股本 7786.91万
- 歷史最高 822.60
- 量 比 1.16
- 振 幅 7.00%
- 歷史最低 1.81
- 每 手 1
- 風險率 2.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Solid Biosciences to Participate at Upcoming Investor Conferences
Solid Biosciences Inc. will participate in four investor conferences in September 2025, with CEO Bo Cumbo engaging in fireside chats at each event. The chats will be live streamed via webcasts available on the company's Events page, with replays archived for 90 days. Institutional investors can schedule one-on-one meetings with management through the conference hosts. Solid Biosciences focuses on developing gene therapies for rare neuromuscular a...
08-28 12:00
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $14
Wedbush analyst Laura Chico maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and lowers the price target from $17 to $14.
08-13 22:44
Solid Biosciences Q2 EPS $(0.42) Beats $(0.53) Estimate
Solid Biosciences (NASDAQ:SLDB) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.53) by 20 percent. This is a 31.15 percent increase over losses of $(0.61) per share from
08-13 04:36
Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates
Solid Biosciences reported Q2 2025 financials with $268.1M in cash and updates on their neuromuscular and cardiac programs. SGT-003 for Duchenne has dosed 15 participants across multiple cohorts with no treatment-emergent SAEs. SGT-212 for FA and SGT-501 for CPVT are expected to initiate Phase 1b trials in Q4 2025. The company anticipates FDA discussions for SGT-003 in Q4 2025 and expects a strong cash runway into H1 2027.
08-12 20:07
Citizens JMP Remains a Buy on Solid Biosciences (SLDB)
Citizens JMP analyst Silvan Tuerkcan reiterated a Buy rating on Solid Bioscienc...
07-24 16:55
Solid Biosciences shares are trading higher after the company announced it received FDA Fast Track Designation status for SGT-501 gene therapy.
Solid Biosciences shares are trading higher after the company announced it rece...
07-23 22:46
Solid Biosciences to begin testing SGT-501 in U.S. and Canada
Solid Biosciences (NASDAQ:SLDB) said that the U.S. FDA and Health Canada has approved its gene therapy, SGT-501,for the treatment of heart disease caused by genetic disorder. The company expects to in...
07-09 21:36
Solid Biosciences Receives FDA IND And Health Canada CTA Approval For First-In-Class Cardiac Gene Therapy To Treat Catecholaminergic Polymorphic Ventricular Tachycardia
- SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies -- SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA
07-09 04:08
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
